Andrew Milstead

Andrew Milstead is a scientist and innovator specializing in drug delivery and nanoparticle research. Currently, they serve as a Principal Scientist in RNA Formulation at Eli Lilly and Company, where they focus on advancing drug delivery methods. Andrew's previous experience includes roles as a Chemist II at AbbVie and a Scientist at Generation Bio, where they developed targeted lipid and polymer-based nanoparticle systems. Their academic background includes a Master's of Science in Chemistry from the University of Massachusetts Dartmouth, where they also completed their Bachelor of Science in Chemistry. Throughout their career, Andrew has made significant contributions to various research projects and has demonstrated expertise in analytical techniques.